Description
A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively)
Formal name: 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
Synonyms: AMN107
Molecular weight: 529.5
CAS: 641571-10-0
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/S||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling